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Abstract
Background: Recent experimental studies have shown that Bcl-2, which has been established as
a key player in the control of apoptosis, plays a role in regulating the cell cycle and proliferation.
The aim of this study was to investigate the relationship between Bcl-2 and p27 protein expression,
p53 protein expression and the proliferation activity as defined by the MIB-1 counts. The
prognostic implication of Bcl-2 protein expression in relation to p27 and p53 protein expressions
and MIB-1 counts for breast cancer was also evaluated.
Methods: The immunohistochemical expression of Bcl-2 protein was evaluated in a series of 249
invasive ductal carcinomas of the breast, in which p27 and p53 protein expressions and MIB-1
counts had been determined previously.
Results: The Bcl-2 protein expression was found to be decreased in 105 (42%) cases. A decreased
Bcl-2 protein expression was significantly correlated with a nuclear grade of III, a negative estrogen
receptor, a decreased p27 protein expression, a positive p53 protein expression, positive MIB-1
counts and a positive HER2 protein expression. The incidence of a nuclear grade of III and positive
MIB-1 counts increased as the number of abnormal findings of Bcl-2, p27 and p53 protein
expressions increased. A univariate analysis indicated a decreased Bcl-2 protein expression to be
significantly (p = 0.0089) associated with a worse disease free survival (DFS), while a multivariate
analysis indicated the lymph node status and MIB-1 counts to be independently significant
prognostic factors for the DFS.
Conclusion: The Bcl-2 protein expression has a close correlation with p27 and p53 protein
expressions and the proliferation activity determined by MIB-1 counts in invasive ductal carcinoma
of the breast. The prognostic value of Bcl-2 as well as p27 and p53 protein expressions was
dependent on the proliferation activity in breast cancer.
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Backgroud
The Bcl-2, first discovered in follicular and diffuse lym-
phomas possessing t(14;18) chromosomal translocation,
has been established as a key regulator of apoptosis [1]. A
decreased expression of Bcl-2 protein was shown to be
associated with a poor clinical outcome in various human
cancers including breast cancer [2-7]. Although Bcl-2 had
been first thought to inhibit cell death without affecting
cell proliferation, recent experimental studies have clari-
fied the role of Bcl-2 in regulating the cell cycle and prolif-
eration and that the Bcl-2 increased the level of p27 to
regulate the cell cycle and progression [9-13]. Only a few
studies, however, have investigated the relationship
between Bcl-2 and p27 protein expressions in tumor spec-
imens [14,15], while there have been many studies on the
prognostic value of either Bcl-2 or p27 protein expression
in various cancers [2-8,14,16-21]. The aim of this study,
therefore, was to investigate the relationship between Bcl-
2 and p27 protein expressions in breast cancer specimens,
and the relationship between Bcl-2 protein expression
and p53 protein expression, the proliferation activity as
defined by the MIB-1 counts and HER2 protein expression
was investigated. The prognostic implication of Bcl-2 pro-
tein expression in relation to p27 and p53 protein expres-




This study comprised 249 consecutive women with breast
cancer who underwent surgery for breast cancer between
1985 and 1998 at the Beppu Medical Center Hospital,
without any evidence of distant metastasis at the time of
surgery. The histological type of breast cancer in all
patients was invasive ductal carcinoma, while types other
than invasive ductal carcinoma or non-invasive carci-
noma were excluded in this study. The patients' ages
ranged from 23 to 86 years, with a mean age of 58.1 years.
The patients were treated either by a mastectomy (211
patients) or by breast conservation treatment (38
patients). Lymph node dissection was performed in 247
patients. Adjuvant postoperative hormone therapy was
given to 220 patients and 215 patients received adjuvant
postoperative chemotherapy, while 54 patients received
postoperative radiotherapy. The median follow-up dura-
tion was 6.6 years. The institutional ethics committee
granted ethical approval for the study. Although the
informed consent was obtained for recent samples, it was
not standard practice to obtain it for older samples.
Immunohistochemistry
For the immunohistochemical analyses, 3-μm sections for
Bcl-2 protein were dewaxed and rehydrated, and antigen
retrieval was performed by microwave heating for 15 min-
utes in a 10 mM citrate buffer at pH 6.0. Next, the sections
were reacted with mouse monoclonal antibody for Bcl-2
(Dako Japan, Kyoto, Japan) diluted at 1:100 for 60 min-
utes at room temperature, and then were subsequently
stained using the universal immuno-peroxidase polymer
method with a Histofine Simple Stain MAX PO(M) kit
(Nichirei Corp., Tokyo, Japan) according to the protocol
provided by the manufacturer. Positive reaction was visu-
alized with diaminobenzidine, followed by counterstain-
ing with hematoxylin. The sections from normal tonsillar
tissue specimens were used as positive controls, while
negative controls were performed by omitting the primary
antibody.
The positivity of Bcl-2 protein expression was defined as
having decreased when less than 25% of the tumor cells
displayed a distinct cytoplasmic staining, since the cut-off
values of 25% have been most frequently employed for
Bcl-2 protein expressions [4,5]. The Bcl-2 protein expres-
sion was determined independently by three authors (S.
T., K. Y. and S. E.) in whom two authors did not know any
clinicopathological information for each patient. The
methods and results of assessing p27, p53 and HER2 pro-
tein expressions and MIB-1 counts were described previ-
ously [22-24].
Statistical analysis
The chi-squared test was used to investigate categorical
variables. The disease free survival (DFS) was estimated
using the Kaplan and Meier method, and any differences
in the survival curves were compared by the Log-rank test.
A multivariate analysis was performed by Cox's propor-
tional hazards model. A p value of < 0.05 was regarded as
statistically significant. All statistical analyses were per-
formed using the StatView 5.0 software (SAS institute Inc.,
Cary, NC, USA).
Results
The Bcl-2 protein expression was determined to be nor-
mal in 144 (58 %) and decreased in 105 (42%) cases (Fig.
1). Table 1 shows the relationship between Bcl-2 protein
expression and the clinicopathological factors including
p27 and p53 protein expressions and MIB-1 counts in the
breast cancers. The decreased expression of Bcl-2 protein
significantly correlated with a nuclear grade of III, a nega-
tive estrogen receptor, a decreased p27 protein expression,
a positive p53 protein expression and positive MIB-1
counts, while a decreased Bcl-2 protein expression was not
significantly correlated with tumor size and lymph node
metastasis. Table 2 shows the relationship between Bcl-2
and HER2 protein expression in 59 patients. The
decreased expression of Bcl-2 protein significantly corre-
lated with a positive expression of HER2 protein.
The positive expression of p53 protein and the decreased
expression of p27 protein had been demonstrated to beBMC Cancer 2006, 6:187 http://www.biomedcentral.com/1471-2407/6/187
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associated with a nuclear grade of III and positive MIB-1
counts in our previous studies [22,23]. Table 3 shows the
incidence of nuclear grade and MIB-1counts in relation to
the combination of the abnormalities in Bcl-2, p27 and
p53 protein expressions. The incidence of a nuclear grade
of III and positive MIB-1 counts increased as the number
of abnormal findings of Bcl-2, p27 and p53 protein
expressions increased. There was a significant (p <
0.0001) correlation between the incidence of nuclear
grade and MIB-1 counts and the number of abnormal
findings of Bcl-2, p27 and p53 protein expressions.
Univariate analyses for DFS indicated the patients with a
decreased Bcl-2 protein expression demonstrated a signif-
icantly (p = 0.0089) worse DFS than those with a normal
Bcl-2 protein expression (Fig. 2). The significant differ-
ence in the DFS was also demonstrated in the 110 patients
with lymph nodes metastases (Fig. 3), while no significant
difference in the DFS was found in 137 patients without
lymph node metastases (Fig. 4). On the other hand, a
multivariate analysis for the DFS indicated the lymph
node status and MIB-1 counts to be independently signif-
icant prognostic factors for the DFS, while neither Bcl-2,
p27 nor p53 protein expressions were independently sig-
nificant prognostic factors for the DFS (Table 4).
Discussion
The present study demonstrated a close correlation
between Bcl-2 and p27 protein expressions regarding
invasive ductal carcinoma of the breast. The decreased
expression of Bcl-2 protein was significantly correlated to
the decreased expression of p27 protein. Although there
have been many studies on the prognostic value of each of
Bcl-2 and p27 protein expressions in various human can-
cers [2-8,14,16-21], only a few studies have been con-
ducted regarding the relationship between Bcl-2 and p27
protein expressions in the tumor specimens [14,15]. A sig-
nificant correlation between Bcl-2 and p27 protein expres-
sions was found in breast cancer specimens [14], while no
correlation was found between the two protein expres-
sions in oral and oropharygeal cancers [15].
Although the role of Bcl-2 has been established as a key
player in the control of apoptosis, recent experimental
studies have demonstrated Bcl-2 to be implicated in regu-
lating the cell cycle and proliferation [9]. The Bcl-2 defi-
cient T cells demonstrated an accelerated cell cycle
progression [10]. On the other hand, the cells overex-
pressing the Bcl-2 gene product not only showed a
delayed onset of apoptosis but also a rapid arrest in the G1
phase of the cell cycle [11], thus suggesting that Bcl-2
played a role in the transition from G0/G1 to S phase [9].
Futhermore, Linette et al. demonstrated that the increased
level of Bcl-2 retarded the G0 to S transition, sustained the
levels of p27 and repressed postactivation death [10].
Vairo et al. also demonstrated the Bcl-2 to retard the cell
cycle entry by increasing the p27 and p130 levels [12].
Greider et al. demonstrated that Bcl-2 was unable to delay
the S phase entry in p27 null cells, thus suggesting that
p27 is required for the cell cycle regulation of Bcl-2 [13].
These experimental findings indicated that Bcl-2 directly
increased the level of p27 [10,12,13], thereby regulating
the cell cycle and progression [9].
The loss of the p53 function represents the most common
genetic change known in human cancers. The present
study demonstrated a significant correlation between p53
and Bcl-2 protein expressions in breast cancer. A signifi-
cant inverse correlation was also demonstrated between
the p53 and Bcl-2 protein expressions [2-5,10], while no
correlation was found in other studies [9,14,18,20].
Immunohistochemical expression of Bcl-2 protein in breast  cancer Figure 1
Immunohistochemical expression of Bcl-2 protein in breast 
cancer. A: a case with a normal expression of Bcl-2 protein in 
breast cancer cells. B: a case with a decreased expression of 
Bcl-2 protein, in which the expression of Bcl-2 protein of 
breast cancer cells decreased in comparison to a normal 
expression of Bcl-2 protein in normal mammary gland.BMC Cancer 2006, 6:187 http://www.biomedcentral.com/1471-2407/6/187
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Haldar et al. showed that the overexpression of mutant
p53 in breast cancer (MCF-7) cell line induced the down-
regulation of Bcl-2 at both the protein and mRNA levels
[25]. On the other hand, the proliferation index is a
potent biological marker which can be used to estimate
the growth of tumors quantitatively and can aid in deter-
mining the prognosis. MIB-1 is expressed throughout the
cell cycle in proliferating cells, but not in cells in either the
G0 phase or the early G1 phase. The Bcl-2 protein expres-
sion was demonstrated to be associated with a high prolif-
erative activity as measured by the S phase fraction in
breast and colon cancers or the 3H thymidine labeling
index in breast cancer [2,3,9].
The Bcl-2 protein expression correlated inversely with the
HER2 expression. We previously found the ER status to
correlate inversely with HER2 expression and that the
patients with a positive HER2 expression had a worse
prognosis than those with a negative HER2 expression
[26], while a positive correlation was found between the
Bcl-2 protein expression and ER status in the present
series. A decrease in Bcl-2 protein expression is associated
Table 2: Relationship between the Bcl-2 and HER2 protein expressions in breast cancer.
No. of patients Bcl-2 protein expression (%) p value
normal decreased
HER2 protein expression 0.0203
0 28 18 (64) 10 (36)
I1 5 6  ( 4 0 ) 9  ( 6 0 )
II 5 0 (0) 5 (100)
III 11 3 (27) 8 (73)
* HER2 protein expression was analyzed in 59 patients
Table 1: Relationship between the Bcl-2 protein expression and the clinicopathological factors in breast cancer.
No. of patients Bcl-2 protein expression (%)
normal decreased p value
Tumor size (cm) 0.0770
- 2.0 57 37 (65) 20 (35)
2.1 – 5.0 162 95 (59) 67 (41)
5.1 - 30 12 (40) 18 (60)
Lymph node metastasis* 0.9507
absent 137 79 (58) 58 (42)
present 110 63 (57) 47 (43)
Nuclear grade < 0.0001
I or II 168 122 (73) 46 (27)
III 81 22 (27) 59 (73)
Estrogen receptor (ER) < 0.0001
positive 109 90 (83) 19 (17)
negative 140 54 (39) 86 (61)
p27 protein expression < 0.0001
normal 140 111 (79) 29 (21)
decreased 109 33 (30) 76 (70)
p53 protein expression < 0.0001
negative 183 123 (67) 60 (33)
positive 66 21 (32) 45 (68)
MIB-1 counts < 0.0001
negative (< 10%) 147 101 (69) 46 (31)
positive (≥ 10%) 102 43 (42) 59 (58)
* Lymph node dissection was performed in 247 patientsBMC Cancer 2006, 6:187 http://www.biomedcentral.com/1471-2407/6/187
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with a high HER2 expression. Freneaux et al. demon-
strated that a higher histological grade, a higher mitotic
index, a higher apoptotic index, and a lower rate of ER
positivity were found in Brca1-associated breast cancers
and that the rate of Bcl-2-positive tumors was lower in
Brca1-associated cancers than in cancers without Brca1
mutation, thus suggesting that the decrease in Bcl-2
expression might account for the high apoptotic and pro-
liferative rates observed in Brca1-associated breast cancers
[27].
In the present study, multivariate analysis determined
only the proliferative activity to be an independently sig-
nificant prognostic factor. The prognostic significance of
Bcl-2 and p27 protein expressions has been well demon-
strated in various cancers [2-8,14,16-21]. Multivariate
analyses determined the Bcl-2 protein expression to be an
independently significant prognostic factor for breast can-
cer [4,6], while other studies, as well as the present study,
determined Bcl-2 protein expression to not be an inde-
pendently significant prognostic factor [2,3]. Whether the
Bcl-2 protein expression is determined to be independ-
ently significant factor or not is due to the relationship
between the Bcl-2 protein expression and the other varia-
bles included in the multivariate models. The prognostic
value of the MIB-1 counts has been demonstrated to be
the most powerful among the nuclear pleomorphim, p53
protein expression and MIB-1 counts in our previous
study [23]. On the other hand, we previously demon-
strated that DNA aneuploidy reflected the accumulation
of the abnormalities in p53 protein expression, epidermal
growth factor receptor, estrogen receptor and progester-
one receptor, thus suggesting that DNA aneuploidy
reflected the accumulation of the aggressiveness of these
biological parameters [28]. In the present study, the inci-
dence of the positive MIB-1 counts increased as the
number of abnormalities regarding the Bcl-2, p27 and
The disease free survival curves stratified by the Bcl-2 pro- tein expressions in the 110 patients with lymph node metas- tases Figure 3
The disease free survival curves stratified by the Bcl-2 pro-
tein expressions in the 110 patients with lymph node metas-
tases.
Table 3: Nuclear pleomorphism and MIB-1 counts in relation to the number of abnormal findings in Bcl-2, p27 and p53 protein 
expressions.
No. of abnormal 
findings in Bcl-2, p27 
and p53 protein 
expressions*
No. of patients Nuclear grade ** MIB-1 counts ***
I or II III negative positive
no 97 92 (95) 5 (5) 76 (78) 21 (22)
one 59 38 (64) 21 (36) 35 (59) 24 (41)
two 58 28 (48) 30 (52) 24 (41) 34 (59)
all (three) 35 10 (29) 25 (71) 12 (34) 23 (66)
* Abnormal findings in Bcl-2 and p27 protein expressions were defined as a decreased expression, while an abnormal finding in p53 protein 
expression was defined as a positive expression.
** p < 0.0001, *** p < 0.0001
The disease free survival curves stratified by the Bcl-2 pro- tein expressions in all 249 patients Figure 2
The disease free survival curves stratified by the Bcl-2 pro-
tein expressions in all 249 patients.BMC Cancer 2006, 6:187 http://www.biomedcentral.com/1471-2407/6/187
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p53 protein expressions increased, thus suggesting that
the proliferative activity determined by the MIB-1 counts
reflected the accumulation of abnormalities in the Bcl-2,
p27 and p53 protein expressions. This finding may
account for the MIB-1 counts showing the most powerful
prognostic value in the multivariate analysis.
Conclusion
The present study demonstrated the Bcl-2 protein expres-
sion to be closely correlated with the p27 and p53 protein
expressions and the proliferation activity determined by
the MIB-1 counts in breast cancer. The incidence of posi-
tive MIB-1 counts increased as the number of abnormali-
ties regarding the Bcl-2, p27 and p53 protein expressions
increased, while only the proliferation activity was deter-
mined to be an independently significant prognostic fac-
tor based by multivariate analyses. These findings
indicated that the prognostic implications of the Bcl-2,
p27 and p53 protein expressions were dependent on the
proliferation activity in breast cancer.
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Table 4: Multivariate analyses for DFS.
Variables p value relative risk 95% CI
Tumor size (cm):
2.1 – 5.0 (vs. – 2.0) 0.8905 1.06 0.49–2.26
5.1 – (vs. – 2.0) 0.2467 1.72 0.69–4.29
Lymph node metastasis:
present (vs. absent) <0.0001 6.14 3.30–11.4
Nuclear grade:
III (vs. I or II) 0.2791 1.39 0.77–2.52
Estrogen receptor:
negative (vs. positive) 0.8502 1.06 0.59–1.89
p27 protein expression:
decreased (vs. normal) 0.8976 1.04 0.58–1.85
p53 protein expression:
positive (vs. negative) 0.3988 1.29 0.71–2.34
MIB-1 counts:
10%≤ (vs.<10%) 0.0029 2.29 1.33–3.96
Bcl-2 protein:
decreased (vs. normal) 0.4037 1.34 0.68–2.64
The disease free survival curves stratified by the Bcl-2 pro- tein expressions in the 137 patients without lymph node  metastases Figure 4
The disease free survival curves stratified by the Bcl-2 pro-
tein expressions in the 137 patients without lymph node 
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